HCW Biologics Inc. Research and Development Expense
HCW Biologics Inc. (HCWB) reported Research and Development Expense of $1.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- HCW Biologics Inc. research and development expense for the quarter ending 2026-06-30 was $1.20M, a 1.91% decline year-over-year.
- HCW Biologics Inc. research and development expense for the quarter ending 2026-03-31 was $1.26M, a 14.93% decline year-over-year.
- HCW Biologics Inc. research and development expense for the quarter ending 2025-12-31 was $1.33M, a 27.01% increase year-over-year.
- HCW Biologics Inc. research and development expense for the quarter ending 2025-09-30 was $1.40M, a 18.31% increase year-over-year.
- HCW Biologics Inc. research and development expense for fiscal 2025 was $5.44M, a 14.81% decline from fiscal 2024.
- HCW Biologics Inc. research and development expense for fiscal 2024 was $6.39M, a 16.77% decline from fiscal 2023.
- HCW Biologics Inc. research and development expense for fiscal 2023 was $7.68M, a 17.80% decline from fiscal 2022.
- HCW Biologics Inc. research and development expense for fiscal 2022 was $9.34M, a 14.25% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.20M 10-Q · filed 2026-08-14 | $2.46M 10-Q · filed 2026-08-14 | $3.79M derived: sum of 3 quarters · filed 2026-08-14 | $5.20M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.26M 10-Q/A · filed 2026-08-14 | $2.59M derived: sum of 2 quarters · filed 2026-08-14 | $4.00M derived: sum of 3 quarters · filed 2026-08-14 | $5.22M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.74M derived: sum of 2 quarters · filed 2026-03-31 | $3.96M derived: sum of 3 quarters · filed 2026-08-14 | $5.44M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.40M 10-Q · filed 2025-11-14 | $2.63M derived: sum of 2 quarters · filed 2026-08-14 | $4.11M 10-Q · filed 2025-11-14 | $5.16M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.23M 10-Q · filed 2026-08-14 | $2.71M 10-Q · filed 2026-08-14 | $3.76M derived: sum of 3 quarters · filed 2026-08-14 | $4.94M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.48M 10-Q/A · filed 2026-08-14 | $2.53M derived: sum of 2 quarters · filed 2026-08-14 | $3.72M derived: sum of 3 quarters · filed 2026-08-14 | $5.74M derived: sum of 4 quarters · filed 2026-08-14 |
| 2024-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.24M derived: sum of 2 quarters · filed 2026-03-31 | $4.27M derived: sum of 3 quarters · filed 2026-03-31 | $6.39M 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.19M 10-Q · filed 2025-11-14 | $3.22M derived: sum of 2 quarters · filed 2025-11-14 | $5.34M 10-Q · filed 2025-11-14 | $7.48M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $2.03M 10-Q · filed 2025-08-18 | $4.15M 10-Q · filed 2025-08-18 | $6.29M derived: sum of 3 quarters · filed 2025-08-18 | $7.96M derived: sum of 4 quarters · filed 2025-08-18 |
| 2024-03-31 | $2.12M 10-Q · filed 2025-05-15 | $4.26M derived: sum of 2 quarters · filed 2025-05-15 | $5.93M derived: sum of 3 quarters · filed 2025-05-15 | $7.54M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $3.80M derived: sum of 2 quarters · filed 2025-03-28 | $5.42M derived: sum of 3 quarters · filed 2025-03-28 | $7.68M 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.67M 10-Q · filed 2024-11-14 | $3.28M derived: sum of 2 quarters · filed 2024-11-14 | $5.54M 10-Q · filed 2024-11-14 | $8.47M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.62M 10-Q · filed 2024-08-14 | $3.87M 10-Q · filed 2024-08-14 | $6.80M derived: sum of 3 quarters · filed 2024-08-14 | $9.45M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $2.26M 10-Q · filed 2024-05-15 | $5.19M derived: sum of 2 quarters · filed 2024-05-15 | $7.83M derived: sum of 3 quarters · filed 2024-05-15 | $9.80M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $2.93M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-15 | $5.58M derived: sum of 2 quarters · filed 2024-05-15 | $7.55M derived: sum of 3 quarters · filed 2024-05-15 | $9.34M 10-K/A · filed 2024-05-15 |
| 2022-09-30 | $2.65M 10-Q · filed 2023-11-14 | $4.62M derived: sum of 2 quarters · filed 2023-11-14 | $6.41M 10-Q · filed 2023-11-14 | $7.89M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.97M 10-Q · filed 2023-08-11 | $3.76M 10-Q · filed 2023-08-11 | $5.24M derived: sum of 3 quarters · filed 2023-08-11 | $7.93M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $1.79M 10-Q/A · filed 2023-08-10 | $3.27M derived: sum of 2 quarters · filed 2023-08-10 | $5.96M derived: sum of 3 quarters · filed 2023-08-10 | $7.63M derived: sum of 4 quarters · filed 2023-08-10 |
| 2021-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $4.17M derived: sum of 2 quarters · filed 2023-03-28 | $5.84M derived: sum of 3 quarters · filed 2023-03-28 | $8.17M 10-K · filed 2023-03-28 |
| 2021-09-30 | $2.69M 10-Q · filed 2022-11-07 | $4.36M derived: sum of 2 quarters · filed 2022-11-07 | $6.69M 10-Q · filed 2022-11-07 | $8.10M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $1.67M 10-Q · filed 2022-08-12 | $4.00M 10-Q · filed 2022-08-12 | $5.41M derived: sum of 3 quarters · filed 2022-08-12 | $7.51M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $2.33M 10-Q · filed 2022-05-13 | $3.74M derived: sum of 2 quarters · filed 2022-05-13 | $5.84M derived: sum of 3 quarters · filed 2022-05-13 | $7.91M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $3.51M derived: sum of 2 quarters · filed 2022-03-29 | $5.58M derived: sum of 3 quarters · filed 2022-03-29 | $7.26M 10-K · filed 2022-03-29 |
| 2020-09-30 | $2.10M 10-Q · filed 2021-11-12 | $4.17M derived: sum of 2 quarters · filed 2021-11-12 | $5.85M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $2.07M 10-Q · filed 2021-08-13 | $3.75M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |